The ability to identify powerful growth trends is an important aspect of successful long-term investing. Businesses with strong competitive positions in rapidly growing industries can compound investors' returns for years and even decades.
確定強勁增長趨勢的能力是成功長期投資的一個重要方面。在快速增長的行業中擁有強大競爭地位的企業，可以在數年乃至幾十年內為投資者帶來豐厚的回報。
Perhaps no other industry is expanding faster than marijuana. The legal marijuana market will grow to more than $146 billion by 2025, according to Grand View Research, up from only $7 billion in 2016.
也許沒有哪個行業比大麻發展得更快。根據 Grand View Research 的數據，到2025年，合法的大麻市場將增長到1460億美元以上，而2016年只有70億美元。
This explosive growth makes the marijuana industry fertile ground for finding excellent long-term investment opportunities. The following three businesses are particularly well positioned to profit from the cannabis market's torrid expansion in the coming decade.
這種爆炸性的增長使大麻產業成為尋找優秀長期投資機會的沃土。以下三家企業特別有能力從大麻市場在未來十年的急劇擴張中獲利。
Altria (NYSE: MO) may not be the first company that comes to mind when thinking about marijuana, but the tobacco titan is likely to emerge as a powerful force within this booming industry.
奧馳亞（ NYSE ： MO ）可能不是第一個想到大麻的公司，但菸草巨頭可能會成為這個蓬勃發展的行業中的強大力量。
Altria made an aggressive move into the cannabis market with its $1.8 billion investment in Cronos Group (NASDAQ: CRON). Altria now owns a 45% stake in the Canadian marijuana producer, along with warrants that give it the right to boost its stake to 55%.
奧馳亞在克羅諾斯集團（ NASDAQ ： CRON ）投資18億美元，大舉進軍大麻市場。奧馳亞現在擁有加拿大大麻生產商45%的股份，同時還擁有將其股份提高到55%的權利。
Altria's regulatory and marketing expertise should help Cronos Group capture a larger share of the global marijuana market in the coming years. Additionally, the strong and steady cash flow Altria produces from its core tobacco business to help lower its risk profile for investors. Altria could also use some of this cash to acquire the remainder of Cronos Group's shares in the future, as well as other cannabis-focused businesses. Altria's investment in Cronos Group may be its first foray in the marijuana industry -- but it's unlikely to be its last.
奧馳亞的監管和營銷專業知識應有助於克羅諾斯集團在未來幾年佔據全球大麻市場的更大份額。此外，奧馳亞的強勁而穩定的現金流來自其核心菸草業務，以幫助降低投資者的風險狀況。奧馳亞還可以用部分現金收購克羅諾斯集團未來的剩餘股份，以及其他以大麻為重點的業務。奧馳亞對克羅諾斯集團的投資可能是其在大麻產業的首次嘗試，但不太可能是最後一次。
Notably, Altria also pays a bountiful dividend, providing its shareholders with a reliable and steadily growing income stream. Its shares currently yield 5.8% and can be had for only 12 times forward earnings -- a bargain price for such a high-quality business.
值得注意的是，奧馳亞也支付了豐厚的股息，為股東提供了可靠且穩定增長的收入流。它的股票目前收益率為5.8%，只能獲得12倍的預期收益——對於這樣一個高質量的企業來說，這是一個便宜的價格。
Now that it is becoming legal in more locations, some people may choose to use marijuana as a substitute for alcohol. Alcoholic beverage behemoth Constellation Brands (NYSE: STZ)(NYSE: STZ-B) knows this. It also had the foresight to partner with a leading marijuana producer, thereby transforming it into a powerful ally, rather than a threat.
現在大麻在更多的地方變得合法，一些人可能會選擇用大麻來代替酒精。酒精飲料巨頭星座品牌（ NYSE ： STZ ）（ NYSE ： STZ-B ）知道這一點。它也有遠見與領先的大麻生產商合作，從而將其轉變為強大的盟友，而不是威脅。
Constellation Brands has invested more than $4 billion in top Canadian marijuana producer Canopy Growth (NYSE: CGC), giving it a 38% stake in the fast-growing company. The capital injection is helping Canopy Growth add production capacity and expand internationally. Constellation and Canopy are also expected to work together to produce cannabis-infused beverages.
Constellation Brands 已向加拿大最大的大麻生產商 Canopy Growth 投資超過40億美元（ NYSE ： CGC ），使其擁有這家快速增長公司38%的股份。此次注資有助於 Canopy Growth 增加產能，並在國際上擴張。預計星座和 Canopy 也將合作生產大麻飲料。
繼續閱讀星座品牌和 IIPR分析，點擊瞭解更多
閱讀更多 匯眾醫療 的文章
